Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Prospective, Single-arm, Multi-center Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With Ocrelizumab

NCT04377555 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT04377555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04377555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Prospective, Single-arm, Multi-center Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With Ocrelizumab
Lead sponsor
Genentech, Inc.
Phase
Phase 4
Overall status
Completed
Start date
July 30, 2020
Completion date
November 11, 2025
Enrollment
179 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, relapsing